Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two decades of pediatric celiac disease in a tertiary referral center: What has changed?
Krauthammer A, Guz-Mark A, Zevit N, Marderfeld L, Waisbourd-Zinman O, Silbermintz A, Mozer-Glassberg Y, Nachmias Friedler V, Rozenfeld Bar Lev M, Matar M, Assa A, Shamir R. Krauthammer A, et al. Among authors: assa a. Dig Liver Dis. 2020 Apr;52(4):457-461. doi: 10.1016/j.dld.2020.02.001. Epub 2020 Feb 26. Dig Liver Dis. 2020. PMID: 32111387
Drugs in Focus: Domperidone.
Puoti MG, Assa A, Benninga M, Broekaert IJ, Carpi FJM, Deganello Saccomani M, Dolinsek J, Homan M, Mas E, Miele E, Tzivinikos C, Thomson M, Borrelli O. Puoti MG, et al. Among authors: assa a. J Pediatr Gastroenterol Nutr. 2023 Aug 1;77(2):e13-e22. doi: 10.1097/MPG.0000000000003822. Epub 2023 May 9. J Pediatr Gastroenterol Nutr. 2023. PMID: 37159421 Review.
Ustekinumab for Resistant Pediatric Crohn Disease.
Rinawi F, Rosenbach Y, Assa A, Shamir R. Rinawi F, et al. Among authors: assa a. J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):e34-5. doi: 10.1097/MPG.0000000000000503. J Pediatr Gastroenterol Nutr. 2016. PMID: 25023579 No abstract available.
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S. Yanai H, et al. Among authors: assa a. Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25. Clin Gastroenterol Hepatol. 2015. PMID: 25066837
Authors' Response.
Rinawi F, Rosenbach Y, Assa A, Shamir R. Rinawi F, et al. Among authors: assa a. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):e30. doi: 10.1097/MPG.0000000000000607. J Pediatr Gastroenterol Nutr. 2016. PMID: 26907227 No abstract available.
166 results